Medical University of Silesia

sum.edu.pl

Total trials

107

Active

22

Phase 3

6

Total enrollment

51,280

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 14 of 14 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Group B1
Group O1
Pembrolizumab1
omalizumab1
NOAC1
Postoperative pain management with acetaminophen1
Postoperative pain management with dexketoprofen1
Postoperative pain management with metamizole1
Preemptive Analgesics1
Administration of a single or repeated dose of a long half-life antibiotic - oritavancin1
Administration of a repeated dose of a short half-life antibiotic - vancomycin1
Subgingival application of 1.2% lovastatin1
Subgingival application of placebo gel1
Clobetasol propionate 0.05 percent topical application1

Next readouts

  • 2025-06-01
  • 2026-06-28
  • 2026-07
  • 2026-10
  • 2026-10-01
  • 2026-12
  • 2027-05
  • 2027-10-31

Top conditions

  • Temporomandibular Disorder5
  • Predictive Value of Tests4
  • Vitreoretinal Surgeries3
  • Postoperative Nausea and Vomiting3
  • Postoperative Pain3
  • Myofascial Pain3
  • Coronary Artery Calcification3
  • Coronary Artery Disease3

Frequently asked questions about Medical University of Silesia

How many clinical trials does Medical University of Silesia have on ClinicalTrials.gov?
Medical University of Silesia is listed as the lead sponsor on 107 clinical trials in ClinicalTrials.gov, 22 of which are currently active (recruiting, enrolling, or ongoing).
How many of Medical University of Silesia's trials are in Phase 3?
6 of Medical University of Silesia's trials are in Phase 3, spread across 14 active drug programs.
What therapeutic areas does Medical University of Silesia focus on?
Medical University of Silesia's most-studied conditions on ClinicalTrials.gov are Temporomandibular Disorder, Predictive Value of Tests, Vitreoretinal Surgeries, Postoperative Nausea and Vomiting, Postoperative Pain.
When are Medical University of Silesia's next clinical trial readouts?
Medical University of Silesia has 8 upcoming primary-completion readouts tracked here; the soonest is “The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab”, expected around 2025-06-01.